MétaCan
Menu
← Back to cohort

MP53-03 REAL-WORLD RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

2024· article· en· W4394802129 on OpenAlexaboutno aff
Sandra Kim, Josh Ma, Nimira Alimohamed, Girish S. Kulkarni, Peter Chung, Jeffrey Graham, Rodney H. Breau, Michael Ong, Éric Lévesque, Naveen S. Basappa, Ricardo Rendon, Jean Castilloux, Eric Winquist, Robert Siemens, Jean‐Baptiste Lattouf, Som D. Mukherjee, Daniel Yokom, Wassim Kassouf, Peter C. Black

Bibliographic record

VenueThe Journal of Urology · 2024
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsMetastatic Urothelial CarcinomaChemotherapyMedicineOncologyImmunotherapyCancerInternal medicineUrothelial carcinomaBladder cancer

Abstract

fetched live from OpenAlex

You have accessJournal of UrologyBladder Cancer: Invasive V (MP53)1 May 2024MP53-03 REAL-WORLD RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA Sandra Kim, Josh Ma, Bernie Eigl, Nimira Alimohamed, Girish Kulkarni, Peter Chung, Jeffrey Graham, Rodney Breau, Michael Ong, Eric Levesque, Naveen Basappa, Ricardo Rendon, Jean Castilloux, Eric Winquist, Robert Siemens, Jean-Baptiste Lattouf, Som Mukherjee, Daniel Yokom, Wassim Kassouf, and Peter Black Sandra KimSandra Kim , Josh MaJosh Ma , Bernie EiglBernie Eigl , Nimira AlimohamedNimira Alimohamed , Girish KulkarniGirish Kulkarni , Peter ChungPeter Chung , Jeffrey GrahamJeffrey Graham , Rodney BreauRodney Breau , Michael OngMichael Ong , Eric LevesqueEric Levesque , Naveen BasappaNaveen Basappa , Ricardo RendonRicardo Rendon , Jean CastillouxJean Castilloux , Eric WinquistEric Winquist , Robert SiemensRobert Siemens , Jean-Baptiste LattoufJean-Baptiste Lattouf , Som MukherjeeSom Mukherjee , Daniel YokomDaniel Yokom , Wassim KassoufWassim Kassouf , and Peter BlackPeter Black View All Author Informationhttps://doi.org/10.1097/01.JU.0001008784.37684.bd.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Contemporary real-world reports of outcomes for patients with locally advanced or metastatic (LA/mUC) urothelial carcinoma are limited. Especially with the advent of switch maintenance immunotherapy and the availability of established second and third line treatment options, it has become imperative to better characterize real-world patient outcomes after first line chemotherapy. The objective of this study was to determine real world practice patterns and outcomes after first line platinum-based chemotherapy in a large multi-centre cohort of LA/mUC. METHODS: The Canadian Bladder Cancer Information System (CBCIS) is a national prospectively maintained database across 15 academic institutions in Canada. Patients who received systemic therapy for locally advanced (cT4b or cN1-3) or metastatic urothelial carcinoma of the bladder were included between January 2015 and April 2023. Patients were included if they had to have at least one follow-up imaging after the initiation of systemic therapy. Treatment parameters and response rates were assessed. RESULTS: A total of 501 patients received first line systemic therapy for LA/mUC of whom 370 (73.9%) received platinum-based chemotherapy. Of those receiving platinum-based chemotherapy, 190 (51.4%) patients received cisplatin/gemcitabine and 172 (46.5%) patients received carboplatin/gemcitabine. Treatment was completed in 97 (26%) of 370 patients and discontinued in 140 (37.8%). Fourty-seven (33.8%) patients stopped treatment due to progression and 68 (48.9%) due to an adverse event. Of the 370 patients undergoing platinum-based chemotherapy with documented response status, complete response was observed in 4 (1.1%) patients, partial response or stable disease in 121 (32.9%) patients, and progression in 99 (26.9%) patients. Second line systemic therapy was administered to 245 (48.9%) patients who received first line systemic therapy. Switch maintenance with avelumab was used in 59 (15.9%) patients after platinum based chemotherapy. The median follow-up from the time of diagnosis was 10.4 months. CONCLUSIONS: The real-world response rates after first line platinum-based chemotherapy in this study are lower than previously reported. This study highlights the need for further research to better evaluate the true real-world effects of treatment in locally advanced and metastatic urothelial carcinoma. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e863 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Sandra Kim More articles by this author Josh Ma More articles by this author Bernie Eigl More articles by this author Nimira Alimohamed More articles by this author Girish Kulkarni More articles by this author Peter Chung More articles by this author Jeffrey Graham More articles by this author Rodney Breau More articles by this author Michael Ong More articles by this author Eric Levesque More articles by this author Naveen Basappa More articles by this author Ricardo Rendon More articles by this author Jean Castilloux More articles by this author Eric Winquist More articles by this author Robert Siemens More articles by this author Jean-Baptiste Lattouf More articles by this author Som Mukherjee More articles by this author Daniel Yokom More articles by this author Wassim Kassouf More articles by this author Peter Black More articles by this author Expand All Advertisement PDF downloadLoading ...

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.023

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0070.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.327
Teacher spread0.302 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of Urology→Same topicBladder and Urothelial Cancer Treatments→French-language works237,207→